Arovella Therapeutics Limited (ASX:ALA)
Australia flag Australia · Delayed Price · Currency is AUD
0.0890
+0.0040 (4.71%)
Feb 19, 2026, 4:10 PM AEST

Arovella Therapeutics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Revenue
0.140.020.410.30.26
Other Revenue
3.31.941.05-0.73
3.441.951.450.30.99
Revenue Growth (YoY)
76.22%34.20%391.75%-70.11%-20.91%
Cost of Revenue
--0.20.210.24
Gross Profit
3.441.951.250.090.75
Selling, General & Admin
2.211.361.51.321.31
Research & Development
6.526.743.982.60.71
Other Operating Expenses
1.651.642.72.632
Operating Expenses
11.3410.839.887.694.7
Operating Income
-7.9-8.88-8.63-7.6-3.96
Interest Expense
--0.01-0-0.19-0.03
Interest & Investment Income
0.390.140.0300.01
Other Non Operating Income (Expenses)
---0.02-0-0.01
EBT Excluding Unusual Items
-7.51-8.75-8.62-7.79-3.98
Asset Writedown
---1.56-0.83-1.24
Other Unusual Items
----0.17
Pretax Income
-7.51-8.75-10.18-8.62-5.05
Earnings From Continuing Operations
-7.51-8.75-10.18-8.62-5.05
Net Income to Company
-7.51-8.75-10.18-8.62-5.05
Net Income
-7.51-8.75-10.18-8.62-5.05
Net Income to Common
-7.51-8.75-10.18-8.62-5.05
Shares Outstanding (Basic)
1,097941711550331
Shares Outstanding (Diluted)
1,097941711550331
Shares Change (YoY)
16.55%32.32%29.45%66.10%132.61%
EPS (Basic)
-0.01-0.01-0.01-0.02-0.02
EPS (Diluted)
-0.01-0.01-0.01-0.02-0.02
Free Cash Flow
-7.34-7.04-6.4-6.3-3.71
Free Cash Flow Per Share
-0.01-0.01-0.01-0.01-0.01
Gross Margin
100.00%100.00%86.01%30.00%75.29%
Operating Margin
-229.61%-454.69%-593.40%-2568.01%-399.66%
Profit Margin
-218.28%-448.03%-699.91%-2914.23%-509.99%
Free Cash Flow Margin
-213.45%-360.80%-439.99%-2130.85%-374.92%
EBITDA
-7.79-8.83-8.53-7.46-3.82
EBITDA Margin
-226.49%----
D&A For EBITDA
0.110.040.10.140.14
EBIT
-7.9-8.88-8.63-7.6-3.96
EBIT Margin
-229.61%----
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.